NHS England has acknowledged that key data does not substantiate the effectiveness of Palantir's technology. The health service added a caveat stating that reported performance improvements cannot, in fact, be attributed to the £330 million contract with Palantir. This admission comes amidst growing scrutiny regarding the impact of the US company's technology within the UK healthcare system.
Further analysis indicates that the reported improvements attributed to Palantir relied on data from only a few hospitals. Problematically, some trusts have even delivered fewer operations since integrating Palantir's controversial technology. This finding directly contradicts claims of operational efficiency gains, raising questions about the true value and efficacy of the software within the NHS.
Despite these concerns and the official admission by NHS England, there is still a push from some officials, including the NHS data chief, for a deeper rollout of Palantir technology. This move, which comes amid an outcry from various quarters, highlights an ongoing debate within the NHS regarding its partnership with Palantir and the justification for its continued use, especially given the lack of conclusive evidence supporting its effectiveness. Pro-Palantir data has also been identified to have a litany of errors, with four hospital trusts confirming inaccuracies in underlying hospital discharge delay data.
